At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
AZD2423 +1 moredrug
Likely dose
AZD2423 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel Group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients With Moderate to Severe COPD
In Brief
A Phase 2 clinical trial evaluating AZD2423 and Placebo to AZD2423 for Chronic Obstructive Pulmonary Disease and Lung Disease. Completed, enrolled 63 participants across 6 sites in 2 countries.
Detailed Summary
The purpose of the study is to investigate the tolerability and safety of AZD2423 in Patients with chronic obstructive pulmonary disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBulgaria, Slovakia
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedOct 2010
Primary CompletionMar 2011
TodayJul 2026
First PostedOct 6, 2010
Enrollment StartOct 1, 2010
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.7 years ago
Interventions
AZD2423drug
100 mg oral treatment once daily for 28 days
Placebo to AZD2423drug
Oral treatment once daily for 28 days